Nuvalent, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NUVL Nasdaq 2836 www.nuvalent.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Nuvalent, Inc.

Nuvalent (NASDAQ:NUVL) Is In A Good Position To Deliver On Growth Plans - Feb 5th, 2025 4:14 pm
Is Nuvalent, Inc. (NUVL) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Jan 20th, 2025 8:07 pm
Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones - Jan 13th, 2025 11:30 am
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Dec 30th, 2024 2:43 pm
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Dec 19th, 2024 11:30 am
Nuvalent Appoints Grant Bogle to Board of Directors - Dec 9th, 2024 11:30 am
Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference - Nov 26th, 2024 11:52 am
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results - Nov 12th, 2024 11:30 am
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates - Sep 19th, 2024 1:21 pm
Nuvalent Announces Closing of Upsized Public Offering of Common Stock - Sep 18th, 2024 8:05 pm
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally? - Sep 18th, 2024 6:26 pm
Company News for Sep 17, 2024 - Sep 17th, 2024 9:28 am
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock - Sep 17th, 2024 2:23 am
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths - Sep 16th, 2024 8:04 pm
Nuvalent Announces Public Offering of Common Stock - Sep 16th, 2024 11:00 am
Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks - Sep 14th, 2024 11:57 pm
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock - Sep 14th, 2024 9:29 pm
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines - Sep 14th, 2024 9:00 am
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655 - Sep 13th, 2024 1:53 pm
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles - Sep 9th, 2024 10:30 am